Prion protein self-interactions: A gateway to novel therapeutic strategies?
نویسندگان
چکیده
منابع مشابه
Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer
Therapy-resistance and postoperative recurrence are causes of the poor prognosis in pancreatic cancer. Conventional therapies have a limited impact on the control of pancreatic cancer, resulting in the rapid re-growth of the tumor. The indispensable role of tumor-stromal interaction, which acts as a defender of cancer cells and enhances malignant potential, is being uncovered now. For example, ...
متن کاملReview: prion protein and amyloid beta interactions
In 2009 it was discovered that prion protein (PrP) binds amyloid beta oligomers (Aβo), potentially acting as a receptor on the surface of neurons. PrP was additionally suggested to mediate at least some of the toxic effects of Aβo in Alzheimer’s disease (AD), a proposition which has proven enormously controversial. In the past three years, several studies have produced apparently strong evidenc...
متن کاملAptamers to explore prion protein interactions with nucleic acids.
A misfolded isoform of the prion protein (PrP) is the essential component of the prion diseases' agent. The prion concept has progressively gained acceptance, in a large part thanks to the realization that it played a role not only in the transmissible spongiform encephalopathies, but also in the non-Mendelian propagation of self-perpetuating phenotypes of the yeast Saccharomyces cerevisiae. Un...
متن کاملFactors affecting interactions between prion protein isoforms.
Interactions between normal, protease-sensitive prion protein (PrP-sen or PrP(C)) and its protease-resistant isoform (PrP-res or PrP(Sc)) are critical in transmissible spongiform encephalopathy (TSE) diseases. To investigate the propagation of PrP-res between cells we tested whether PrP-res in scrapie brain microsomes can induce the conversion of PrP-sen to PrP-res if the PrP-sen is bound to un...
متن کاملCharacterization and Targeting of Thromboxane Receptor Dimerization: A Gateway to Novel Therapeutic Developments
Thromboxane A2 (TXA2) contributes to cardiovascular disease (CVD) by activating platelets and vascular smooth muscle cell constriction and proliferation. Despite their preclinical efficacy, pharmacological antagonists of the TXA2 receptor (the TP), a G protein-coupled receptor (GPCR), have not been clinically successful, raising interest in novel approaches to modifying TP function. We sought t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Vaccine
سال: 2010
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2010.09.012